The news comes shortly after AZ announced positive results from a late-stage trial of the drug.
News
Finals day location confirmed for the 2019 Marketer of the year competition
IQVIA have been confirmed to host the finals days for the 2019 PharmaTimes Marketer of the Year and also the Sales Awards at their offices in Reading.
AZ presents strong H1 financial results
The sales numbers were boosted by oncology drugs such as Tagrisso, Imfinzi and Lynparza.
Janssen’s ponesimod holds up against Aubagio in late-stage trial
The drug is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.
First convergent science centre launched in UK
Scientists are “re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles”.
ViiV submits regulatory application to EMA for investigational HIV combo
The application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV.
Skin cancer rates rocket 45% in 10 years
Rates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men.
NHS Confederation responds to PM’s promise to ‘fix crisis’
But the organisation says it will “need more details of exactly how this will be achieved”.
FDA accepts Brinavess resubmission
The FDA initially cited insufficient data and refused to accept the initial submission in August 2017.
New inquiry into healthy ageing launched
Increasing health span has been adopted as a policy objective by the UK Government in the Industrial Strategy’s “Ageing Society”.
Lynparza now available on Cancer Drugs Fund
The treatment reduces the risk of disease progression or death in such patients by 70% vs placebo.
CHMP recommends five new medicines
Stelara, Keytruda and Tecentriq were also among the extensions of therapeutic indication.
£20m investment to help young people find NHS careers
The funding will support 10,000 young people from all backgrounds to get a career in the NHS.
GSK Q2 figures boosted by vaccine sales
The company has readjusted its prediction for its earnings per share to decline in the range of -3% to -5% at CER, as opposed to the previous -5% to -9%.
NICE to form alliance to produce chronic asthma guideline
The guideline aims to support health professionals in making accurate diagnoses and providing effective treatments.
